Hallucinations

XPhyto Therapeutics Corp. Featured in Syndicated Broadcast Covering Latest Progress Report on Mescaline Program for Psychedelic Therapies

Tuesday, June 15, 2021 - 4:10pm

The audio press release covers XPhytos recent announcement regarding the status of its GMP mescaline synthesis program.

Key Points: 
  • The audio press release covers XPhytos recent announcement regarding the status of its GMP mescaline synthesis program.
  • To hear the audio production, visit: https://www.nnw.fm/GFUhh
    To read the original press release, visit: https://www.nnw.fm/dcaCA
    "With both its North American GMP mescaline synthesis program and German-based psilocybin biotechnology production underway, the first stage of XPhyto's psychedelic medicine program is progressing on schedule.
  • As the manufacturing programs advance, we look forward to focusing our expertise on psychedelic drug formulation," said Hugh Rogers, CEO & Director.
  • IBN is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions.

Dimensions Health Centres to Provide Funding for Psychedelics Research Collaborative at Queen’s University

Tuesday, June 15, 2021 - 1:30pm

TORONTO, June 15, 2021 (GLOBE NEWSWIRE) -- Dimensions Health Centres (Dimensions), a psychedelic wellness companyoffering immersive retreats for reset and renewal,will provide funding to the Faculty of Health Sciences at Queens University, to help launch a collaborative space for research and innovation in the field of psychedelics.

Key Points: 
  • TORONTO, June 15, 2021 (GLOBE NEWSWIRE) -- Dimensions Health Centres (Dimensions), a psychedelic wellness companyoffering immersive retreats for reset and renewal,will provide funding to the Faculty of Health Sciences at Queens University, to help launch a collaborative space for research and innovation in the field of psychedelics.
  • The Dimensions Health Fund in support of the Study of Psychedelics will assist Queens in launching a psychedelics research collaborative, which will take a multi-pronged approach to fostering research and innovation in psychedelic-focused therapies.
  • We are confident that the research and development at Queens will shape the psychedelics industry for years to come.
  • Founded in Toronto in 2021, Dimensions is a founding partner of the Psychedelics Research Collaborative at Queens University.

CURE Pharmaceutical to Present at H.C. Wainwright 2021 Psychedelics in Psychiatry and Beyond Virtual Conference

Tuesday, June 15, 2021 - 1:15pm

"The potential therapeutic benefits of psychedelics to treat mental health disorders is significant.

Key Points: 
  • "The potential therapeutic benefits of psychedelics to treat mental health disorders is significant.
  • I am very proud that we have been able to commence development of our psychedelics-based pharmaceutical clinical pipeline," Berlent said.
  • The presentation can be viewed beginning at 7:00 a.m. EST on June 17 after registering at https://hcwevents.com/psychedelics/ .
  • To schedule a one-on-one meeting with management, please follow the instructions in the link above or reach out to your H.C. Wainwright representatives directly.

InterVivo Solutions Provides Update on Cooperative Psychedelics Evaluation Platform (COPE) - Names Drs. Inés De Lannoy and Lilia Magomedova to Lead Bioanalytical Platform Development

Saturday, June 12, 2021 - 2:00pm

Assuming these relationships apply to other reference psychedelics, this data should enable back translation of human clinical study data to IVS' behavioral models.

Key Points: 
  • Assuming these relationships apply to other reference psychedelics, this data should enable back translation of human clinical study data to IVS' behavioral models.
  • Sponsors will be able to submit their in-life samples for analysis at InterVivo's bioanalytical lab, centrally located in the Greater Toronto Area.
  • Ins de Lannoy and Lilia Magomedova, who are overseeing its development and application to profiling the pharmacokinetics properties of the selected psychedelic molecules.
  • Mindset was established to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs.

Join us for World Psychedelics Day – June 20th (6·20)

Friday, June 11, 2021 - 2:45pm

Themes slated for this years World Psychedelics Day include:

Key Points: 
  • Themes slated for this years World Psychedelics Day include:
    The full speaker list and programming schedule can be found here.
  • A global event uniting the psychedelic community, World Psychedelics Day is proud to work with our wonderful partners.
  • In addition to a full day of engaging conversations on fascinating topics, World Psychedelics Day will host public art projects, and present relevant documentaries.
  • World Psychedelics Day 620, 2021 is a project of the International Psychedelics Awareness Foundation, a Canadian non-profit organization of artists, journalists, university students, parents, and businesspeople.

Bright Minds Biosciences to Present at the H.C. Wainwright Virtual Conference Psychedelics in Psychiatry and Beyond

Friday, June 11, 2021 - 1:00pm

The presentation will be webcast beginning at the aforementioned time and available for 7 days thereafter using the link provided above.

Key Points: 
  • The presentation will be webcast beginning at the aforementioned time and available for 7 days thereafter using the link provided above.
  • Bright Minds is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain.
  • Bright Minds has a portfolio of next generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors.
  • Bright Minds drugs extenuate the therapeutic aspects of psychedelic and other serotonergic compounds while minimizing the side effects thereby creating superior drugs to first generation compounds, such as psilocybin.

Entheon Biomedical's Wholly-Owned Subsidiary, HaluGen Life Sciences, Psychedelics Genetic Test Kit Now Available for Sale in US

Thursday, June 10, 2021 - 1:30pm

HaluGen Life Sciences' test evaluates an individual's overall sensitivity and risk profile associated with psychedelic-assisted therapy

Key Points: 
  • The Psychedelics Genetic Test Kit, a first of its kind, was designed and commercialized by HaluGen, and launched in Canada on April 5, 2021.
  • The Psychedelics Genetic Test Kit provides users with personalized reports and actionable insights, delivered directly to one's smartphone or desktop through the HaluGen website customer platform, providing a convenient and safe means to better understand one's sensitivity to psychedelics and ketamine.
  • The test also provides insights into the short and long-term potential of psychedelic-induced risks, such as psychosis.
  • Psychedelics Genetic Test Kit customers receive a swab kit that is shipped directly to their home and the unique kit identifier is registered on HaluGen's secure online portal.

PSYC Continues to Amass Sizable Audience Within Emerging Medicinal Psychedelics Industry

Thursday, June 10, 2021 - 1:30pm

The Company contends that this encouraging data, observed from Google Analytics, demonstrates the growing audience and following it continues to amass within the emerging sector of medicinal psychedelics, and more specifically, at a time when the industry itself continues to garner more attention from the mainstream media.

Key Points: 
  • The Company contends that this encouraging data, observed from Google Analytics, demonstrates the growing audience and following it continues to amass within the emerging sector of medicinal psychedelics, and more specifically, at a time when the industry itself continues to garner more attention from the mainstream media.
  • Regardless of the industry, I truly believe there is a significant amount of value in a company establishing a large following and audience, Said Global Trac Solutions, Inc. CEO, David Flores.
  • And from my perspective, with the psychedelics industry still very much in its infancy, I cant help but to see the advantageous and opportunistic position that, in my opinion, we are creating for PSYC through the success of Psychedelic Spotlight.
  • PSYC is your source for current investment related news specific to psychedelic medicines and cutting-edge research improving overall health, moving this sector into the mainstream.

Awakn Life Sciences to Participate in the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference

Thursday, June 10, 2021 - 1:00pm

Toronto, Ontario--(Newsfile Corp. - June 10, 2021) - Awakn Life Sciences Inc. (Awakn), a biotechnology company with clinical operations researching, developing, and delivering psychedelic medicine to treat Addiction, announced today that Anthony Tennyson, Chief Executive Officer, and Professor Celia Morgan, Head of Awakn's Ketamine-Assisted Psychotherapy for Addiction Practice, will participate in H.C. Wainwright's Psychedelics in Psychiatry and Beyond Virtual Conference panels on Thursday, June 17, 2021.

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - June 10, 2021) - Awakn Life Sciences Inc. (Awakn), a biotechnology company with clinical operations researching, developing, and delivering psychedelic medicine to treat Addiction, announced today that Anthony Tennyson, Chief Executive Officer, and Professor Celia Morgan, Head of Awakn's Ketamine-Assisted Psychotherapy for Addiction Practice, will participate in H.C. Wainwright's Psychedelics in Psychiatry and Beyond Virtual Conference panels on Thursday, June 17, 2021.
  • For more information regarding the conference, or to schedule a one-on-one meeting with Awakn's management team, please contact KCSA Strategic Communications at Awakn@KCSA.com or your H.C. Wainwright representatives directly.
  • About Awakn Life Sciences Inc.
    Awakn Life Sciences is a biotechnology company with clinical operations researching, developing, and delivering psychedelic medicine to treat Addiction.
  • Awakn is integrating psychedelic medicine into mainstream healthcare through Research, Digital, Clinics, and Ecosystems.

PharmaTher Provides Research and Development Update and Milestones for 2021

Thursday, June 10, 2021 - 1:00pm

TORONTO, June 10, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the Company or PharmaTher) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to provide an update on the research and development initiatives of its psychedelic product programs and upcoming milestones for 2021.

Key Points: 
  • TORONTO, June 10, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the Company or PharmaTher) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to provide an update on the research and development initiatives of its psychedelic product programs and upcoming milestones for 2021.
  • Interim development results will be made available as they arise throughout 2021.
  • Interim development results will be made available as they arise throughout 2021.
  • PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is a clinical-stage psychedelics biotech company focused on the research, development and commercialization of novel uses, formulations and delivery methods of psychedelics to treat mental health, neurological and pain disorders.